Related Experiment Video
Updated: Apr 7, 2026
08:57
Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
Published on: March 26, 2015
28.0K
Dl-3-n-butylphthalide is effective for demyelination: a case-combined study
Yuan Wu1, Qi Huang1, Xixia Liu1
1Department of Neurology, First Affiliated Hospital of Guangxi Medical University, 6th Shuangyong Road, Nanning, Guangxi 530021, China.
Clinical Neurology and Neurosurgery
|July 13, 2015
Summary
Dl-3-n-butylphthalide shows promise in treating demyelinating diseases, improving patient symptoms and MRI results. This compound protected white matter in a rat model by regulating apoptosis.
Area of Science:
- Neurology
- Neuroscience
- Pharmacology
Background:
- Demyelinating diseases present significant challenges in neurology due to unclear treatment options.
- A heroin-addicted patient with altered mental status exhibited white matter abnormalities indicative of demyelination on MRI.
Purpose of the Study:
- To investigate the therapeutic potential of Dl-3-n-butylphthalide in a patient with demyelinating disease.
- To evaluate the efficacy of Dl-3-n-butylphthalide in a rat model of demyelination.
Main Methods:
- Clinical case presentation of a patient with demyelination treated with Dl-3-n-butylphthalide.
- Induction of demyelination in a rat model using ethidium bromide.
- Assessment of treatment effects using MRI, EEG, and histological analysis.
Main Results:
- High-dose methylprednisolone was ineffective in the patient.
- Intravenous Dl-3-n-butylphthalide treatment led to clinical improvement and normalization of EEG and MRI findings.
- Dl-3-n-butylphthalide demonstrated a protective effect against white matter demyelination in the rat model, involving regulation of apoptosis.
Conclusions:
- Dl-3-n-butylphthalide represents a potential novel therapeutic agent for demyelinating diseases.
- The compound's mechanism may involve the regulation of apoptotic pathways in white matter protection.
